uniQure N.V. Proceeds from Long-Term Debt Issued
uniQure N.V. (QURE) reported Proceeds from Long-Term Debt Issued of $64.07 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2024-02-28
- uniQure N.V. proceeds from issuance of long-term debt for the quarter ending 2021-12-31 was $29.46M.
- uniQure N.V. proceeds from issuance of long-term debt for the quarter ending 2021-09-30 was $0.00.
- uniQure N.V. proceeds from issuance of long-term debt for the quarter ending 2021-06-30 was $0.00.
- uniQure N.V. proceeds from issuance of long-term debt for the quarter ending 2021-03-31 was $34.60M.
- uniQure N.V. proceeds from issuance of long-term debt for fiscal 2021 was $64.07M.
- uniQure N.V. proceeds from issuance of long-term debt for fiscal 2018 was $14.78M.
- uniQure N.V. proceeds from issuance of long-term debt for fiscal 2014 was $9.54M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2021-12-31 | $29.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $29.46M derived: sum of 2 quarters · filed 2024-02-28 | $29.46M derived: sum of 3 quarters · filed 2024-02-28 | $64.07M 10-K · filed 2024-02-28 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $34.60M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $34.60M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $34.60M 10-Q · filed 2022-05-02 | |||
| 2018-12-31 | $14.78M 10-K · filed 2021-03-01 | |||
| 2014-12-31 | $9.54M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |